Partners HealthCare News

Translate Bio Announces Pricing of Initial Public Offering

August 3, 2018

Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross…

Read More

Next Chapter For Biotech? Many Say 'Convergence' With Data Science

June 13, 2018

by WBUR June 8, 2018- So far, the digital revolution has mostly been a disappointment in health care. Doctors stare at their screens instead of us. Specialists and emergency rooms still don’t have all our records. But artificial intelligence, big data analytics and deep learning are converging on health care in a big way, information…

Read More

Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-long-acting Oral Dosage Form for Chinese Market

May 8, 2018

Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China. Lyndra is developing ultra-long-acting oral therapies that free patients…

Read More

Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

April 6, 2018

Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced treatment of the first patient with an inherited metabolic disorder in a Phase 2 study of MGTA-456.

Read More

Denali Therapeutics prices IPO at $18 midpoint making it the largest biotech IPO of the year

December 8, 2017

Denali Therapeutics, a an early-stage biotech developing novel therapies for neurodegenerative diseases, raised $250 million by offering 13.9 million shares at $18, within the range of $17 to $19. At pricing, the company commands a fully diluted market value of $1.7 billion.  

Read More

Spero Therapeutics Announces Closing of Initial Public Offering

November 7, 2017

Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions.  In addition, Spero Therapeutics, Inc. has granted the…

Read More

Spero Therapeutics Announces Pricing of Initial Public Offering

November 2, 2017

Two biotechs, Spero Therapeutics and Allena Therapeutics, are headed for the Nasdaq this morning at valuations they’d been aiming for. Their stock offerings are the latest sign of the health of the biotech IPO market, and the willingness of insiders to make sure these deals succeed. For more information, click here

Read More

Fierce Biotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017

September 27, 2017

Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative hematopoietic stem cell transplantation for more patients, today announced that it has been named by FierceBiotech as one of the Fierce 15 biotechnology companies of 2017. This award designates Magenta Therapeutics as one of the most promising private biotechnology companies…

Read More

Call for Submissions! The Philips Wearables Challenge

August 31, 2017

Call for Submissions! Philips Wearables Challenge  The Philips Wearables Challenge is a call for novel solutions to predict early signs of patient deterioration in order to prevent hospital readmission and escalation in care throughout the patient journey. What cutting edge technologies and systems — wireless wearable sensors, connected devices, continuous, real-time monitoring, data analytics, etc. — can…

Read More

AI and GE – The Disruption Accelerates

July 11, 2017

On May 17, Partners HealthCare joined forces with another Boston institution, GE Electric Co., to launch an ambitious 10-year collaboration to rapidly develop, validate, and strategically integrate deep learning technology into every aspect of the patient journey. Working with GE Healthcare, this decade-long effort will be executed through the newly formed Massachusetts General Hospital and…

Read More

Hospital owner eyes cutting-edge therapies

October 24, 2016

Hospital owner eyes cutting-edge therapies Partners parceling out $1 million in grants by Lindsay Kalter, Boston Herald Saturday, October 22, 2016   Boston-based medical giant Partners HealthCare is doling out $1 million in grants to get cutting-edge therapies from food allergy cures to scarless biopsies on the market within five to seven years, and at least three…

Read More

QPID Acquired by Leading Technology-Enabled Medical Benefit Management Company eviCore healthcare

February 29, 2016

Leading Technology-Enabled Medical Benefit Management Company eviCore healthcare Acquires QPID Health Combined entity will support healthcare’s shift to value-based care with advanced analytics, software and services to support payers, hospitals, physicians and patients BLUFFTON, SC – February 29, 2016 – eviCore healthcare, a company committed to enabling better outcomes for patients, payers and providers through…

Read More

Editas Medicine pricing shares at $16 for year's first IPO: reports

February 3, 2016

Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4…

Read More

Spero Therapeutics Announces $30 Million Series B Preferred Financing

February 3, 2016

CAMBRIDGE, Massachusetts, February 2, 2016 – Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund will provide $30 million in Preferred B funding. Spero will use proceeds from this financing…

Read More

Proton beam cancer therapy 'effective with fewer side effects'

February 1, 2016

A cancer treatment at the centre of an NHS controversy in 2014 causes fewer side effects in children than conventional radiotherapy, according to new research. The study, published in The Lancet Oncology, suggests proton beam therapy is as effective as other treatments. Researchers looked at 59 patients aged between three and 21 from 2003 to…

Read More

Scientists find possible topical treatment for skin lesions

February 1, 2016

BOSTON, Jan. 29 (UPI) — Researchers at Harvard University found that blocking specific signaling enzymes that contribute to common benign skin lesions called seborrheic keratoses, or SKs, cause them die, according to a new study. The researchers, who work at Massachusetts General Hospital, were investigating why the lesions, which have genetic similarities to cancer, grow…

Read More

Can We Truly "Cure" Cancer?

January 28, 2016

Monica Bertagnolli, WMIF co-chair, chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and chair of the Alliance for Clinical Trials in Oncology, a nationwide effort to test new therapies, speaks on Barack Obama’s aspirational plan in his final State of the Union to “cure cancer.”

Read More

App Gives Clinicians Instant Treatment Options During Critical Events

January 28, 2016

SAN DIEGO—Promoting data sharing and medical device interoperability can help improve patient care and clinical decision making, according to researchers at Massachusetts General Hospital, in Boston. Most medical devices currently used in the operating room environment are not designed to interconnect with each other, according to Julian M. Goldman, MD, an anesthesiologist and medical director…

Read More